Trigeminal Neuralgia (Tic Douloureux) Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Trigeminal
Neuralgia (Tic Douloureux) – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Trigeminal Neuralgia – Pipeline Review, H1 2019 provides comprehensive
information on the therapeutics under development for Trigeminal
Neuralgia (Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Trigeminal Neuralgia (Central Nervous System) pipeline guide also
reviews of key players involved in therapeutic development for
Trigeminal Neuralgia (Tic Douloureux) and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies/Universities/Institutes, the molecules developed by
Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 3, 2,
1 and 2 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 1 molecules, respectively.

Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is
built using data and information sourced from the researcher’s
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured
on a real time basis.

Note: Certain content/sections in the pipeline guide
may be removed or altered based on the availability and relevance of
data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Trigeminal Neuralgia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Trigeminal
  Neuralgia (Central Nervous System) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Trigeminal
  Neuralgia (Central Nervous System) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Trigeminal Neuralgia (Central Nervous
  System) therapeutics based on mechanism of action (MoA), drug target,
  route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Trigeminal Neuralgia (Central Nervous System)

Reasons to buy:

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Trigeminal Neuralgia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus
  of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Involved in Therapeutics Development

• Allergan Plc
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• InMed Pharmaceuticals Inc
• Merz Pharma GmbH & Co KgaA
• PixarBio Corp

Drug Profiles

• carbamazepine
• GTX-201
• incobotulinumtoxin A
• INM-405
• OLP-1002
• onabotulinumtoxinA
• rimegepant
• Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and
  Trigeminal Neuralgia
• vixotrigine

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ntld88/trigeminal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs